Hovione is also present in the inhalation area, and provides a complete range of services, from active pharmaceutical ingredients (APIs), formulation development and devices.

[3] Hovione continues to be a privately held company with 5 plants - in Portugal (1969), Macao (1986), and New Jersey (2001) expanded in 2016,[4] Taizhou in mainland China (2008) and Cork, Ireland (2009) - have a total reactor capacity of 1300 m³ and 1100 people worldwide.

[5][6][7][8] Hovione is a major source of semi-synthetic tetracyclines and corticosteroids, and is the largest independent supplier of contrast agents – these three families of compounds make up most of its generic product portfolio.

The other half of the business focuses on exclusive projects including the development of innovator APIs and particle engineering.

The plan over the next three years is to continue investing, especially in Portugal, where the firm will add 165 m3 of chemical synthesis capacity, a spray-dryer building, and a 1,200-m2 analytical lab.